Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

15.78 +0.07 (+0.45%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
6 Analysts Have This to Say About Bausch & Lomb
 
Via Benzinga
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Earnings Preview: Bausch & Lomb
 
Via Benzinga
Analyst Ratings for Bausch & Lomb
 
Via Benzinga
Analyst Ratings for Bausch & Lomb
 
Via Benzinga
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)... 
Via Benzinga
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Will Acquire XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS